Where is disc medicine?
Disc Medicine is officially headquartered at 321 Arsenal Street, Suite 101, located in Watertown, Massachusetts. Watertown is part of the vibrant Greater Boston biotechnology and life sciences cluster, providing the clinical-stage biopharmaceutical enterprise close proximity to world-class academic institutions, research talent, and medical centers. The company utilizes this headquarters to direct its core operations, corporate strategy, and specialized research programs dedicated to discovering, developing, and commercializing novel treatments for severe hematologic and rare disorders.
Related FAQs
The employee experience at DISC, which is often associated with the healthcare and medical data services sectors, is mixed, with an overall rating of 3.9 out of 5 stars based on employee reviews.
Wall Street analyst consensus price targets for Disc Medicine, Inc. (NASDAQ: IRON) average approximately $68.00, with high-end biotechnology projections extending up to $95.00.
Financial market participants evaluating individual mining or steel-related equities often referred to as iron stocks must examine global industrial demand cycles, raw material pricing trends, and production output from major manufacturing economies.
Disc Medicine (IRON) is viewed by many market analysts as a "Strong Buy," with all 11 analysts covering the stock recommending it as a buy.
Disc Medicine is a biopharmaceutical company that has been developing DISC-0974, an investigational monoclonal antibody designed to treat anemia associated with inflammatory diseases, such as myelofibrosis.
Medical treatments administered via injection for anemia typically involve specialized prescription medications designed to correct iron deficiencies or stimulate red blood cell production when oral supplements are insufficient.
Physical iron or broader iron ore commodity investments are typically evaluated by examining global industrial manufacturing activity, steel production demand from major economies like China, and supply chain dynamics across major mining hubs.
Market professionals generally view Disney (DIS) stock as a favorable buy as of late July 2026, with an overwhelming 93% of analysts recommending either a "Buy" or "Strong Buy" rating.